Genedrive Posts H1 Results with £4.9m Fundraise, Advances NHS and International Commercialisation

Genedrive’s H1 2025/26: fresh cash, NHS traction, and a clearer US route

Genedrive’s interim results land with two big messages: funding risk eased and commercial focus sharpened. The company raised circa £4.9 million net after the period-end and converted a £0.5 million shareholder loan into equity, leaving it debt free with £3.65 million cash at 27 March 2026. Operationally, NHS adoption pathways are firming up for both of its rapid pharmacogenetic tests, with pilots broadening in the UK and first steps taken internationally.

This update matters because it pairs tangible health system progress with the cash to push through the next 6-12 months of commercial execution – when procurement decisions and evidence generation should start to convert into orders.

What Genedrive sells, in plain English

• Genedrive CYP2C19 ID Kit – a rapid genetic test used after ischaemic stroke or TIA to identify patients who will not respond to clopidogrel (a blood thinner), so clinicians can switch therapy quickly.
• Genedrive MT-RNR1 ID Kit – a rapid test in neonatal care to spot babies with a genetic variant that makes aminoglycoside antibiotics likely to cause lifelong hearing loss. It enables an alternative antibiotic to be prescribed in time.

Both tests are CE-IVD approved and recommended by NICE. “Point of care” just means results are delivered fast at the bedside, not sent to a lab.

NHS and international progress: from pilots to procurement

CYP2C19 stroke testing is embedding into care pathways

• In use at Salford Hyper Acute Stroke Unit, the largest in England, within a national pilot supporting broader adoption.
• NHS implementation guidance now published for CYP2C19 testing in stroke pathways, explicitly recognising rapid testing options such as Genedrive’s kit.
• Accepted onto the NHS Dynamic Procurement System (DPS), which lets NHS trusts buy directly via a streamlined route – a practical barrier removed.
• Scotland’s NHS Grampian and Western Isles are running a year-long “test of change” across c.400 patients in remote and rural settings to build the business case for wider roll-out.
• Use-case expansion: a 12-month Acute Coronary Syndrome (ACS) study is underway with Manchester University NHS Foundation Trust and the BHF Centre of Excellence, exploring value in cardiovascular disease.
• US pathway clarified: 510(k) submission currently anticipated around June 2026 (after required studies), with a 3-4 month review target post-submission.

MT-RNR1 newborn testing is scaling and saving hearing

• Now live across 14 UK hospitals through the PALOH-UK evidence generation programme; more than 30 critically ill babies with the MT-RNR1 variant have been identified so far, enabling alternative antibiotics and reducing risk of aminoglycoside-induced hearing loss.
• Scotland has commenced a national phased roll-out, starting at the Royal Hospital for Children in Glasgow, with further sites expected through 2026.
• Rotunda Hospital, Dublin, has implemented the kit to support routine clinical use nationally.
• Saudi Arabia: a Memorandum of Understanding with the Ministry of Health (via Genedrive’s partner) to run a national pilot under the “Generations Hear” initiative.
• US: de novo submission is being planned under Breakthrough Designation.
• Also on the DPS, easing the path to trust-level procurement in England.

Financials at a glance

Revenue and other income (H1)	£0.57m (H1 2024/5: £0.35m)
Diagnostics costs (H1)	£2.3m (H1 2024/5: £2.1m)
Administrative costs (H1)	£856k (H1 2024/5: £862k)
Operating loss (H1)	£2.6m (H1 2024/5: £2.6m)
Loss after tax (H1)	£2.4m (H1 2024/5: £2.3m)
Basic loss per share	0.3p (H1 2024/5: 0.4p)
Cash at 31 Dec 2025	£0.4m
Cash at 27 Mar 2026	£3.65m; debt free
Equity fundraise (post-period)	circa £4.9m net; £0.5m loan converted
Total funding including loan conversion	£5.75m (post-period)
Expected average cash burn (next 6 months)	\~£0.35m per month
Visible FY26 revenue	\~£0.8m

Revenue is still modest, but trending up, and the balance sheet is shored up for the near term. The FY25 R&D tax credit is expected in the coming weeks, which should further support liquidity.

Why this update matters for investors

• Funding buys time to execute. With circa £4.9 million net raised and the loan converted, immediate balance sheet strain has eased, allowing focus on commercial delivery, manufacturing scale-up, and user-led product refinements.
• NHS procurement friction is coming down. DPS listing for both tests is important because it creates a practical route for trusts to place orders without lengthy tenders. Coupled with the NHS implementation guide for CYP2C19 testing, the administrative groundwork is now in place.
• Clinical proof points are accumulating. More than 30 babies identified with MT-RNR1 variants is a small number in absolute terms, but the clinical and human impact is powerful. For CYP2C19, interim national pilot results show rapid testing is feasible and scalable in acute settings.
• International optionality building. Early steps in Ireland and Saudi Arabia, plus defined FDA pathways (510(k) for CYP2C19 around June 2026 and de novo planning for MT-RNR1), broaden the addressable market beyond the UK.

Balanced view: the positives and the pinch points

What looks encouraging

• Stronger cash position post raise, with a guided burn of ~£0.35 million per month and ~£0.8 million FY26 revenue visibility already in hand.
• Formal NHS guidance and DPS acceptance remove major adoption barriers for CYP2C19; Scotland’s national roll-out for MT-RNR1 is a strong endorsement.
• US regulatory pathway clarity for CYP2C19, with a near-term submission target and defined review window.
• ACS study could extend CYP2C19 utility beyond stroke into cardiology, expanding the commercial opportunity.

What to watch carefully

• Going concern flagged: continued viability to June 2027 requires hitting sales targets. If sales undershoot, the Board may need to cut spend or seek further funding.
• NHS funding constraints. The Board expects improvement from April, but on a phased basis that could take up to 12 months – timing remains the key swing factor for revenue conversion.
• Commercial resourcing. The sales team shrank from 11 to 4 due to funding constraints; rebuilding post-raise is sensible but execution capacity has been tight.
• MT-RNR1 timelines. NICE indicates July 2027 to review PALOH-UK outcomes for potential full guidance – near-term adoption relies on local budgets rather than central reimbursement.

Key catalysts over the next 12 months

• FDA 510(k) submission for CYP2C19 around June 2026 and subsequent 3-4 month review window.
• Updates from Scotland’s CYP2C19 “test of change” (c.400 patients) and the Manchester-led ACS study.
• Orders via NHS DPS and progress in Scottish roll-out for MT-RNR1.
• Saudi “Generations Hear” pilot initiation and early outcomes; additional EU/Middle East registrations.
• Revenue beats versus the ~£0.8 million FY26 visibility.
• Cash trajectory against the ~£0.35 million monthly burn; receipt of the FY25 R&D tax credit.

The bottom line

Genedrive has used the post-period raise to stabilise its footing and double down on commercial execution. The NHS groundwork – guidance, DPS access, and live pilots – is now supportive rather than speculative. Internationally, the company is putting pegs in the ground with the US pathway defined for CYP2C19 and pilots emerging in Ireland and Saudi Arabia.

The flip side is that meaningful revenue still depends on local NHS budgets loosening and pilots converting, which the Board expects to happen progressively over the next year. With cash in the bank and a clearer regulatory runway, the next few quarters should tell us how quickly interest turns into signed orders. For now, it is a better-funded, execution-focused story with visible near-term milestones – and that is a notable step forward.